
    
      The study is designed in two parts: A single arm dose escalation phase I part and dose
      expansion phase II part.

      During dose escalation of S65487 in combination with azacitidine, only S65487 agent dose will
      escalate and a DDI (Drug-Drug interaction) assessment between S65487 and posaconazole
      (antifungal drug) will be performed.

      For the expansion phase, Ramp up dose and full dose will be the RP2D (Recommended Phase 2
      Dose) determined during phase I part
    
  